The best characterized hemopoietic growth inhibitors in myeloid leukemias are leukemia associated inhibitor (LAI) and leukemia inhibitory activity (LIA). Both are normal cell products overproduced in leukemia. LIA is identical with acid isoferritins and LAI is not identical with LIA. They act in different ways to inhibit normal stem cell growth. The overproduction of these putative normal regulators may explain the suppression of normal hemopoiesis typical of myeloid leukemias. Modulation of the production and the action of LAI and LIA may have potential therapeutic value in leukemia.
展开▼
